Intoplicine (BioDeep_00000180039)
human metabolite blood metabolite
代谢物信息卡片
化学式: C21H24N4O (348.19500139999997)
中文名称: 茚托利辛
谱图信息:
最多检出来源 Mus musculus(blood) 10%
分子结构信息
SMILES: CC1=CN=C(C2=C1NC3=C2C4=C(C=C3)C=C(C=C4)O)NCCCN(C)C
InChI: InChI=1S/C21H24N4O/c1-13-12-23-21(22-9-4-10-25(2)3)19-18-16-7-6-15(26)11-14(16)5-8-17(18)24-20(13)19/h5-8,11-12,24,26H,4,9-10H2,1-3H3,(H,22,23)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:135474
- PubChem: 65954
- HMDB: HMDB0253504
- DrugBank: DB12868
- ChEMBL: CHEMBL1908351
- CAS: 125974-72-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - R A Newman, J Kim, B M Newman, R Bruno, M Bayssas, M Klink-Alaki, R Pazdur. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
Anti-cancer drugs.
1999 Nov; 10(10):889-94. doi:
10.1097/00001813-199911000-00004. [PMID: 10630356] - R van Gijn, W W ten Bokkel Huinink, S Rodenhuis, J B Vermorken, O van Tellingen, H Rosing, L J van Warmerdam, J H Beijnen. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs.
1999 Jan; 10(1):17-23. doi:
10.1097/00001813-199901000-00003. [PMID: 10194543] - D Abigerges, J P Armand, G G Chabot, R Bruno, M C Bissery, M Bayssas, M Klink-Alakl, M Clavel, G Catimel. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Anti-cancer drugs.
1996 Feb; 7(2):166-74. doi:
10.1097/00001813-199602000-00004. [PMID: 8740721] - J R Eckardt, H A Burris, J G Kuhn, M C Bissery, M Klink-Alakl, G M Clark, D D Von Hoff. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute.
1994 Jan; 86(1):30-3. doi:
10.1093/jnci/86.1.30. [PMID: 8271279] - M C Bissery, C H Nguyen, E Bisagni, P Vrignaud, F Lavelle. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
Investigational new drugs.
1993 Nov; 11(4):263-77. doi:
10.1007/bf00874425. [PMID: 8157469] - R van Gijn, H Rosing, W W ten Bokkel Huinink, O van Tellingen, J B Vermorken, A J Liefting, R Bruno, H M Pinedo, J H Beijnen. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography.
1993 May; 614(2):299-306. doi:
10.1016/0378-4347(93)80322-u. [PMID: 8314943]